Revive Therapeutics Ltd. announced that Tessio Rebello, Ph.D., will join the Company as a clinical advisor for the Company. Dr. Rebello previously held the position of Vice President of Clinical Development at VIRxSYS Corporation where he led the successful launch of anti-sense, gene therapy (VRX496), Phase 2 clinical trial for the treatment of HIV-infected patients who fail to respond to conventional drug therapies and two other Phase 2 clinical trials involving the same drug.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.025 CAD | 0.00% | 0.00% | -16.67% |
1st Jan change | Capi. | |
---|---|---|
-16.67% | 76.53L | |
+10.56% | 12TCr | |
+12.19% | 11TCr | |
-4.62% | 2.47TCr | |
-2.33% | 2.2TCr | |
-6.03% | 1.93TCr | |
-13.53% | 1.76TCr | |
-40.50% | 1.73TCr | |
+6.02% | 1.4TCr | |
+30.35% | 1.21TCr |
- Stock Market
- Equities
- RVV Stock
- News Revive Therapeutics Ltd.
- Revive Therapeutics Appoints Tessio Rebello as Clinical Advisor